Soleno Therapeutics Inc.
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and U.S. Launch Update for VYKAT XR
Summary
Soleno Therapeutics, Inc. reported a strong third quarter 2025 financial performance with net product revenue of $66.0 million and a net income of $26.0 million. The company achieved profitability with positive net income and highlighted the U.S. launch of VYKAT XR, an FDA-approved treatment for hyperphagia in patients with Prader-Willi syndrome (PWS). VYKAT XR has been positively received in the PWS community, with over 1,000 patient start forms received and 764 active patients on the drug as of September 30, 2025. The company also raised $230 million in gross proceeds through an underwritten offering of common stock.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement